Nasdaq grts.

Management criteria checks 3/4. Gritstone bio's CEO is Andrew Allen, appointed in Aug 2015, has a tenure of 8.25 years. total yearly compensation is $2.68M, comprised of 23.2% salary and 76.8% bonuses, including company stock and options. directly owns 1.6% of the company’s shares, worth $2.07M. The average tenure of the management team and ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.16 ต.ค. 2566 ... The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ... GRTS + ...Nov 14, 2023 · Gritstone Bio Inc (NASDAQ:GRTS) trade information. Sporting -3.50% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Monday, 11/13/23 when the GRTS stock price touched $1.38 or saw a rise of 25.61%. Nov 14, 2023 · Gritstone Bio Inc (NASDAQ:GRTS) trade information. Sporting -3.50% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Monday, 11/13/23 when the GRTS stock price touched $1.38 or saw a rise of 25.61%.

EMERYVILLE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...Feb 10,2023 - GRTS STOCK PRICE DECREASE: Gritstone bio Inc on 02-10-2023 decreased stock price > 10% from $3.26 to $2.90. Dec 15,2022 - GRTS STOCK PRICE INCREASE: Gritstone bio Inc on 12-15-2022 increased stock price > 10% from $3.11 to $3.92. Dec 14,2022 - GRTS STOCK PRICE INCREASE: Gritstone bio Inc on 12-14 …EMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

Find the latest Earnings Report Date for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.The 36-month beta value for GRTS is also noteworthy at 0.44. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”. The average price estimated by analysts for GRTS is $10.40, which is $9.08 above than the current price.Financials. GRTS has a market cap of $169mn and a cash balance of $153mn. Research and development expenses were $30.5 million for the three months ended March 31, 2023 while general and ...Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable ...

EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...

MT. B. Riley Initiates Coverage of Gritstone bio With Buy Rating, Price Target of $8 Per Share. Mar. 28. MT. HC Wainwright Adjusts Gritstone bio's Price Target to $7 From $12, Keeps Buy Rating. Nov. 07. MT. Piper Sandler Starts Gritstone bio at Overweight With $6 Price Target.

Sep 27, 2023 · EMERYVILLE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS ), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that it was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phase 2b comparative study ... EMERYVILLE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...EMERYVILLE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...Nov 17, 2023 · Gritstone Bio Inc (NASDAQ:GRTS) showed a performance of -33.50% in past 30-days. Number of shares sold short was 9.12 million shares which calculate 2.48 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $10.40 to the stock, which implies a rise of 86.83% to its current value. Gritstone Bio Inc (NASDAQ: GRTS)’s stock price has soared by 17.69 in relation to previous closing price of 1.30. Nevertheless, the company has seen a gain of 11.68% in its stock price over the last five trading days. Zacks Investment Research reported 2023-10-16 that Gritstone bio Inc. (GRTS) has been upgraded to a Zacks Rank #2 (Buy ...

Jul 4, 2023 · So spare a thought for the long term shareholders of Gritstone bio, Inc. (NASDAQ:GRTS); the share price is down a whopping 70% in the last three years. That might cause some serious doubts about ... The average price predicted for Gritstone Bio Inc (GRTS) by analysts is $10.40, which is $9.08 above the current market price. The public float for GRTS is 87.55M, and at present, short sellers hold a 9.62% of that float. On November 30, 2023, the average trading volume of GRTS was 2.33M shares. The electric vehicle boom is accelerating – …GRTS Historical Data. Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online . The net and ...Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its ...May 3, 2021 · Gritstone bio (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that it was awarded a contract by the Biomedical ...Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer ...

Based on analysts offering 12 month price targets for GRTS in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Jan 13, 2022 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. The average one-year price target for Gritstone Bio (NASDAQ:GRTS) has been revised to 10.71 / share. This is an increase of 22.09% from the prior estimate of 8.77 dated August 31, 2023.Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

About Gritstone bio Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines.

Get the latest GRTS (GRTS) real-time quote, historical performance, charts, and ... Home GRTS • NASDAQ. add. Share. GRTS. $1.88. After Hours: $1.93. ( 2.66%)+ ...

EMERYVILLE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its ...Based on analysts offering 12 month price targets for GRTS in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Find the latest on short interest for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.Analyzing the GRTS fundamentals. Gritstone Bio Inc [NASDAQ:GRTS] reported sales of 400.0 million for the most recent quarter, which represents a drop of -85.51%. A company’s income per employee is -$513,678 while it generates $39,781 in revenue per employee. Gross Margin for this corporation currently stands at -69.28% …A. Gritstone Bio ( GRTS) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual Revenue was $1.6M, which ...

The stock price for Gritstone Bio ( NASDAQ: GRTS) is $ 1.31 last updated Today at November 27, 2023, 10:46 AM PST. Q.WebGritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone ...Instagram:https://instagram. humana loyalty plus reviewcigna dental savings plansis rocket mortgage a good companywhat is the best platform for trading forex Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. fdvv holdingswalmart vista EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ... imnn Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Nov 14, 2023 · Gritstone Bio Inc (NASDAQ:GRTS) trade information. Sporting -3.50% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Monday, 11/13/23 when the GRTS stock price touched $1.38 or saw a rise of 25.61%. Oct 11, 2023 · EMERYVILLE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- October 11, 2023 (GLOBE NEWSWIRE) – Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world ...